December 1, 2020 06:23 AM ESTUpdated 07:30 AM

Roche shelved these psychiatry drugs. So its former head of neuro cooked up some new plans — and raised $59M for his startup

Amber Tong

As the former head of neuroscience product development at Roche for a decade, George Garibaldi can personally vouch for the quality of what the Swiss …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Roche shelved these psychiatry drugs. So its former head of neuro cooked up some new plans — and raised $59M for his startup

Amber Tong

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Revolution’s KRAS drugs appear competitive in several lung cancer settings

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Roche shelved these psy­chi­a­try drugs. So its for­mer head of neu­ro cooked up some new plans — and raised $59M for his start­up

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Roche shelved these psychiatry drugs. So its former head of neuro cooked up some new plans — and raised $59M for his startup